By Rishika Sadam and Kashish Tandon HYDERABAD (Reuters) -Danish drugmaker Novo Nordisk launched its blockbuster weight-loss ...

Wegovy, a weight-loss injection containing semaglutide, has arrived in India, offering a new approach to combatting obesity ...

Luis Alvarez/Getty Images A new study has found that Wegovy helped women lose more weight than ... greater improvements in symptoms with more weight loss. Dr. John Lowe, a Physician at Restore ...

Fact checked by Nick BlackmerFact checked by Nick Blackmer New research found that women with a certain type of heart failure lost more weight on Wegovy than men with the same condition. On ...

Women who take Wegovy to treat obesity have the greatest likelihood of achieving 10% or more weight loss in a ... which comes in a higher dose, is for weight loss while Victoza is for Type 2 diabetes.

People considering weight-loss medications might wonder which one works best, and first-of-its-kind research points to an answer. A new study published in the New England Journal of Medicine ...

There’s no question that the wildly popular injectable weight-loss drugs help people drop pounds, lower heart-disease risk, manage obstructive sleep apnea, and more.But as more people use these ...

People taking Eli Lilly’s obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk’s Wegovy in the first head-to-head study of the blockbuster medications.

Using a random sample of 16 million patients, researchers found that women who newly initiated semaglutide (Ozempic, Wegovy) had a twofold higher risk of hair loss than those starting on the ...

Women with obesity and diabetes taking weight loss and diabetes drugs Mounjaro and Zepbound for over a year lost more weight than their male counterparts—but also experienced more nausea and ...

Danish drugmaker Novo Nordisk on Tuesday launched its blockbuster weight-loss drug Wegovy in India, three months after Eli ...

Wegovy causes greater weight loss but not more benefit The study, which included two trials, involved 1,145 people with HFpEF. Some had diabetes, while others did not.